Abstract Library

Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.

Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.

ENETS Abstract Search

#3074 Medullary Thyroid Carcinoma and DIPNECH: An Unexpected Association

Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine tumour of the C-cells of thyroid gland. Diffuse idiopathic pulmonary neuroendocrine cells hyperplasia (DIPNECH) is a rare condition, thought to be primarily a neuroendocrine proliferative process which can develop into carcinoid tumours.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Lima Ferreira J, Marques B, Elvas A, Simões de Carvalho F, Fonseca A,

Keywords: medullary thyroid cancer, DIPNECH, neuroendocrine tumour, carcinoid tumour, pulmonary nodules,

#3007 An mRNA-based Classifier Identifies PanNETs with Different Clinicopathological Characteristics

Introduction: Pancreatic neuroendocrine tumors (PanNETs) are a heterogeneous group of neoplasms that varies from indolent to highly aggressive diseases. Previous studies have suggested alterations of ATRX/DAXX as biomarkers of dismal prognosis, yet inconclusive data (especially in the metastatic setting) prevent those biomarkers to be used as routine clinical tests.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Vicentini C, Barbi S, Bersani S, Rusev B, Lawlor R,

Keywords: PanNET, gene expression profile, ATRX/DAXX mutations, patients’ stratification.,

#2963 Intrinsic Gene Programs in Metastasis-like Primary Subtype Is Associated with Early Metastatic Evolution in Pancreatic Neuroendocrine Tumours

Introduction: Three molecular subtypes of pancreatic neuroendocrine tumours (PanNETs) have been described: insulinoma-like, intermediate and metastasis-like primary (MLP). The Latter is a non-functional tumours with highly metastatic potential. A mouse model of PanNET showed that MLP subtype has two different pathways of progression including stem/progenitor and epithelial-to-mesenchymal transition. However, the evolution of metastasis in patients requires further studies.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Lawlor R, Nyamundanda G, Ragulan C, Scarpa A,

Keywords: Pancreatic neuroendocrine tumors, metastasis, metastatic evolution, early metastasis, recurrence, prognosis, Patient tumours, cause and effect relationship, computational modeling, molecular subtypes, stages, metastatic potential,

#2218 More than Rare Pheochromocytomas: Bilateral and Hemorrhagic, Giant and Metastatic

Introduction: Pheochromocytomas (PCC) are rare neuroendocrine tumors. These catecholamine-secreting tumors, with an average size of 4.9cm, are multiple in 10% of cases. About 10% are malignant but distant metastases are rare. Non-traumatic adrenal hemorrhage is an unusual potentially fatal event seen in PCC.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Peralta Ferreira M

Authors: Peralta Ferreira M, Sousa Fernandes M, Roque R, Matos C, Strecht J,

Keywords: pheochromocytoma, giant, hemorrhagic, metastatic, bilateral,

#2215 Development of Multiplex Biomarker Assay to Subtype Pancreatic Neuroendocrine Tumors (PanNETs) with Distinct Prognosis and Mutations

Introduction: Overall 5-year survival for PanNETs ranges from 25-100%. The treatment paradigm for PanNETs largely based upon grades, which is significantly heterogeneous. We previously defined three molecular subtypes (distributed grades) of PanNETs using PanNETassigner signature. There is an unmet clinical need for prognostic and predictive biomarkers and clinically-relevant assays to complement grade and improve patient stratification.

Conference: 15th Annual ENETSConcerence (2018)

Presenting Author: Sadanandam A

Authors: Sadanandam A, Young K, Nyamundanda G, Ragulan C, Lawlor R,

Keywords: molecular subtypes, biomarker assay, clinical assay, patient prognosis, subtype-specific mutations, NanoString Technologies, low-cost assay, pancreatic neuroendocrine tumors, grades, PanNETassigner subtype, patient stratification, pnet,